M Hamon

发表

Novel selective and partial agonists of 5-HT3 receptors. Part 1. Synthesis and biological evaluation of piperazinopyrrolothienopyrazines.

P Delagrange, M. Hamon, B. Guardiola-Lemaitre, 1996, Journal of medicinal chemistry.

Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies

M. Hamon, É. Doucet, Y. Sari, 1999, Neuroscience.

Characteristics of [14C]Guanidinium Accumulation in NG 108‐15 Cell Exposed to Serotonin 5‐HT3 Receptor Ligands and Substance P

M. Riad, M. Hamon, M. Emerit, 1993, Journal of neurochemistry.

International Union of Pharmacology. XII. Classification of opioid receptors.

P B Bradley, P. Bradley, M. Hamon, 1996, Pharmacological reviews.

Neurotransmitter transporters in the central nervous system.

M. Hamon, S. El Mestikawy, C. Sagné, 1999, Pharmacological reviews.

The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes.

M. Hamon, L. Lima, M Hamon, 1995, European journal of pharmacology.

Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins.

M. Hamon, S. El Mestikawy, M. Emerit, 1990, Biochemical pharmacology.

5-Hydroxytryptamine (5-HT)1A Autoreceptor Adaptive Changes in Substance P (Neurokinin 1) Receptor Knock-Out Mice Mimic Antidepressant-Induced Desensitization

S. Hunt, L. Lanfumey, M. Hamon, 2001, The Journal of Neuroscience.

Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse.

M. Hamon, L. Lima, M Hamon, 1994, European journal of pharmacology.

Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.

M. Hamon, M. Menziani, É. Doucet, 1999, Journal of medicinal chemistry.

Novel and selective partial agonists of 5-HT3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines.

P Delagrange, M. Hamon, P. Renard, 1997, Journal of medicinal chemistry.

Effects of genetic depletion of monoamines on somatosensory cortical development

P. Gaspar, C. Alvarez, T. Vitalis, 2002, Neuroscience.

Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.

T. Langer, M. Hamon, M. Menziani, 1998, Journal of medicinal chemistry.

Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties.

M. Hamon, M Hamon, J. Adrien, 1988, The Journal of pharmacology and experimental therapeutics.

Somatodendritic localization of 5‐HT1A and preterminal axonal localization of 5‐HT1B serotonin receptors in adult rat brain

L. Descarries, K. C. Watkins, S. Garcia, 2000, The Journal of comparative neurology.

Altered expression and functions of serotonin 5‐HT1A and 5‐HT1B receptors in knock‐out mice lacking the 5‐HT transporter

K. Lesch, L. Lanfumey, M. Martres, 2000, The European journal of neuroscience.

5-HT2A gene promoter polymorphism as a modifying rather than a vulnerability factor in anorexia nervosa

P. Gorwood, M. Hamon, J. Adès, 2002, European Psychiatry.